Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Eton Pharmaceutcials Inc (ETON)

Eton Pharmaceutcials Inc (ETON)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,124
  • Shares Outstanding, K 25,297
  • Annual Sales, $ 21,830 K
  • Annual Income, $ -1,960 K
  • 60-Month Beta 1.40
  • Price/Sales 2.46
  • Price/Cash Flow N/A
  • Price/Book 4.04
Trade ETON with:

Options Overview Details

View History
  • Implied Volatility 130.07% ( -106.04%)
  • Historical Volatility 35.01%
  • IV Percentile 63%
  • IV Rank 24.27%
  • IV High 352.23% on 09/06/22
  • IV Low 58.88% on 06/15/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 1,672
  • Open Int (30-Day) 1,686

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.15
  • Number of Estimates 1
  • High Estimate -0.15
  • Low Estimate -0.15
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +7.69%
on 09/23/22
2.35 -10.64%
on 09/08/22
-0.18 (-7.89%)
since 08/30/22
3-Month
1.95 +7.69%
on 09/23/22
3.25 -35.38%
on 07/18/22
-0.52 (-19.85%)
since 06/30/22
52-Week
1.95 +7.69%
on 09/23/22
6.72 -68.75%
on 11/02/21
-2.94 (-58.33%)
since 09/30/21

Most Recent Stories

More News
Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -300% and 5.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

ETON : 2.10 (-0.94%)
PAHC : 13.29 (+0.91%)
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -150% and 40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ABCL : 9.89 (+0.41%)
ETON : 2.10 (-0.94%)
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 7.64% and 99.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IGMS : 22.74 (+17.04%)
ETON : 2.10 (-0.94%)
Analysts Estimate Fortress Biotech (FBIO) to Report a Decline in Earnings: What to Look Out for

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FBIO : 0.8600 (+0.67%)
ETON : 2.10 (-0.94%)
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: Should You Buy?

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ETON : 2.10 (-0.94%)
ABCL : 9.89 (+0.41%)
Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)

DEER PARK, Ill., July 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing...

ETON : 2.10 (-0.94%)
Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has acquired a...

RDY : 52.34 (+0.23%)
ETON : 2.10 (-0.94%)
Eton Pharmaceuticals Announces Sale of Hospital Products

Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 millionGoing forward, Eton’s commercial...

ETON : 2.10 (-0.94%)
RDY : 52.34 (+0.23%)
Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Lags Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -162.50% and 69.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

ETON : 2.10 (-0.94%)
VYNT : 0.5580 (+0.83%)
Eton Pharmaceuticals Reports First Quarter 2022 Financial Results

DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing...

ETON : 2.10 (-0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

See More

Key Turning Points

3rd Resistance Point 2.22
2nd Resistance Point 2.19
1st Resistance Point 2.14
Last Price 2.10
1st Support Level 2.06
2nd Support Level 2.03
3rd Support Level 1.98

See More

52-Week High 6.72
Fibonacci 61.8% 4.90
Fibonacci 50% 4.34
Fibonacci 38.2% 3.77
Last Price 2.10
52-Week Low 1.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar